Otu ọgwụgwọ

Ọgwụgwọ ndị egosipụtara

CAR-T maka Glioblastoma

Nusinersen Sodium Injection: Olileanya maka Atrophy Muscular Spinal

Usoro ọgwụgwọ CAR-T maka ọrịa kansa afọ

Usoro ọgwụgwọ CAR-T maka Neuroblastoma nlọghachite/naghachi azụ

CAR-T maka usoro Lupus Erythematosus (SLE)

Ọrịa Sickle Cell & Thalassemia

Usoro ọgwụgwọ Gene ọhụrụ na-enye olileanya ọhụrụ maka ndị ọrịa Sickle cell na Thalassemia

FUCASO: Usoro mgbanwe zuru oke-mmadụ BCMA CAR-T na arụmọrụ na nchekwa enweghị atụ.

Ịkwado mkpụrụ ndụ NK: Ịga n'ihu ọgwụgwọ ọrịa cancer gafere oke

Ekpughere TIL Therapy: Na-enyocha mbara ala nke Ọrịa Cancer Immunotherapy

0102030405

Nkọwa zuru oke nke ọgwụgwọ ọrịa leukemia na-emebi ala

Usoro ọgwụgwọ CAR-T, nke dị mkpụmkpụ maka Chimeric Antigen Receptor T-Cell Immunotherapy, bụ usoro ọgwụgwọ mkpụrụ ndụ ihe nketa dị elu nke gụnyere imegharị mkpụrụ ndụ T nke onye ọrịa iji lekwasị anya na ibibi mkpụrụ ndụ kansa. N'adịghị ka ọgwụ ọdịnala, a na-ahazi ọgwụgwọ CAR-T maka onye ọrịa ọ bụla ma na-achọ ịnakọta mkpụrụ ndụ T n'ọbara onye ọrịa tupu iweghachi ha azụ n'ime ahụ mgbe injinịa mkpụrụ ndụ ihe nketa gachara.

Kpọtụrụ anyị

Ngosipụta nke CAR-T

● B-cell nnukwu lymphoblastic leukemia

●Ọtụtụ myeloma

●Ọrịa leukemia lymphocytic na-adịghị ala ala

●Ọrịa lymphoma na-abụghị Hodgkin

●Na-agbasa nnukwu lymphoma B-cell

●Lupus erythematosus (SLE)

●Myasthenia gravis

●Ọrịa autoimmune ndị ọzọ

Ọmarịcha arụmọrụ ụlọ ọgwụ CAR-T

Ngosipụta maka CD19+20CAR-T: Ndị ọrịa nwere lymphoma na-abụghị Hodgkin B-cell

Ọnụego otu ọnwa CR	Ọnụego PR otu ọnwa	Otu ọnwa ma ọ bụ ọnụego	CRS≥3	CRES≥3
71.95% (59/82)	25.6 (21/82)	97.55 (80/82)	12.19% (10/82)	0

Ngosipụta maka CD19+22CAR-T: Ọgwụgwọ nke CD19 nlọghachite na refractory nnukwu B-lymphocytic leukemia ndị ọrịa.

Ọnụego otu ọnwa CR	Ọnụego PR otu ọnwa	Otu ọnwa ma ọ bụ ọnụego	CRS≥3	CRES≥3
92.1% (35/38)	7.9% (3/38)	100% (38/38)	15.79% (6/38)	0

Ngosipụta maka BCMACAR-T: Ọgwụgwọ nke nlọghachi azụ na refractory multiple myeloma

Ọnụego otu ọnwa CR	Ọnụego PR otu ọnwa	Otu ọnwa ma ọ bụ ọnụego	CRS≥3	CRES≥3
72.41% (21/29)	27.59% (8/29)	100% (29/29)	6.9% (2/29)	0

Nlele nyocha nke ọgwụgwọ ụgbọ ala-T (2) tch

Uru Anyị

● Ọgwụgwọ ahaziri onwe ya: A na-ahazi ọgwụgwọ CAR-T ọ bụla maka onye ọrịa, na-ahụ na nsonaazụ ọgwụgwọ ezubere iche na nke dị irè.

● Nhọrọ iche iche iche: Site n'ọtụtụ ụdị antigens lekwasịrị anya, gụnyere CD7, CD19, CD20, CD22, na BCMA, ngwaahịa CAR-T anyị na-enye mgbanwe na-enweghị atụ n'ịgwọ ọrịa ọrịa hematological dị iche iche na ọrịa autoimmune.

● Ihe ịga nke ọma Clinical pụtara: Usoro ọgwụgwọ CAR-T anyị egosipụtala ịdị irè pụrụ iche n'ofe ọtụtụ ikpe ụlọ ọgwụ, yana ọnụego mgbaghara dị egwu na profaịlụ nchekwa, na-ewusi ọnọdụ anyị ike dị ka onye ndu na immunotherapy.

● Ọnụ ego dị elu-arụmọrụ: Anyị na-enye ọnụ ahịa asọmpi na ọgwụgwọ dị elu dị elu na ọnụ ahịa enwere ike ịnweta ma e jiri ya tụnyere ngwaahịa CAR-T ndị ọzọ na ahịa.

● Nkà na ụzụ Cutting-Edge: N'iji ọganihu kachasị ọhụrụ na injinịa mkpụrụ ndụ ihe nketa, usoro ọgwụgwọ CAR-T anyị na-agụnye ọdịnihu nke ọrịa cancer na ọgwụgwọ ọrịa autoimmune.

● Nkwado Clinical ọkachamara: Ndị otu anyị nwere ahụmahụ nke ndị dọkịta na ndị nchọpụta na-enye nlekọta zuru oke site na nyocha mbụ site na nchịkwa ọgwụgwọ na nsonye.

A na-amata mkpụrụ ndụ CAR-T ugbu a maka ịdị irè ha na ndị ọrịa na-anabataghị ọgwụgwọ ọdịnala dị ka chemotherapy ma ọ bụ ntụgharị ụmị ọkpụkpụ. Obodo ahụike zuru ụwa ọnụ na-ekweta ikike mgbawa nke ọgwụgwọ CAR-T n'ịgbanwe nsonaazụ ndị ọrịa.

Ọmụmụ na ikpe metụtara ọgwụgwọ CAR-T

1.CAR-T ọgwụgwọ maka sistem lupus erythematosus: Mmetụta dị ịrịba ama n'ihe gbasara ụmụaka

Otu okwu dị egwu na Ụlọ Ọgwụ Mahadum Erlangen gosipụtara ịdị irè nke ọgwụgwọ cell CAR-T n'ịgwọ nwa agbọghọ dị afọ 15 nwere lupus erythematosus (SLE). N'ịgbaso usoro ọgwụgwọ dara ada, Uresa nwetara ọgwụgwọ ọhụrụ a na June 2023. N'ime izu atọ ka a gwọchara ya, mgbaàmà ya abawanyela nke ukwuu, na-eduga na mgbake zuru oke na mweghachi nke ọrụ akụrụ. Ihe ịga nke ọma a bụ akara izizi nke ọgwụgwọ CAR-T maka ọrịa autoimmune ụmụaka, na-egosipụta ikike ya iji nweta mgbaghara ogologo oge ma gbanwee nsonaazụ onye ọrịa. A na-eme nyocha ọzọ iji nyochaa ngwa ya n'ọnọdụ ndị yiri ya.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2.CAR-T Therapy for Multiple Myeloma: Mgbaghara dị mkpa enwetara

Bjørn Simensen, onye ọrịa dị afọ 67 si Norway, nwetara mgbanwe dị ịrịba ama n'ọgụ ya megide multiple myeloma (IgG lambda, ISS-II) mgbe ọ nwetasịrị ọgwụgwọ cell CAR-T. Achọpụtara ya na mbụ na 2017, ọ nwetara ọtụtụ usoro ọgwụgwọ chemotherapy, mana ọ laghachiri na 2021. N'ịgbaso ọgwụgwọ na-adịghị mma, e zigara ya ụlọ ọgwụ Lu Daopei na February 2022, bụ ebe a họpụtara ya maka ọgwụgwọ CAR-T. Mgbe usoro nhazi ihe gachara, etinyere mkpụrụ ndụ CAR-T ya. Ka ọ na-erule ụbọchị 28, nyocha ndị na-esochi na-egosi na ọ nweghị mkpụrụ ndụ plasma na-adịghị mma n'ime ụmị ọkpụkpụ ya, na-egosi nnukwu ihe ọ rụzuru na ọgwụgwọ ya.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3.CD7 CAR-T ọgwụgwọ maka T-ALL na LBL nlọghachite: arụmọrụ na-ekwe nkwa

Nnyocha e mere n'oge na-adịbeghị anya na-egosi ịdị irè nke CD7 chimeric antigen receptor T-cell (CAR-T) ọgwụgwọ jikọtara ya na nke abụọ allogeneic hematopoietic stem cell transplantation (HSCT) maka ndị ọrịa nwere T-cell nnukwu lymphoblastic leukemia (T-ALL) na lymphoblastic lymphoma (LBL). Emere na ụlọ ọgwụ Hebei Yanda Lu Daopei, ọmụmụ ihe ahụ metụtara ndị ọrịa 16 bụ ndị nwetara ọrịa 100% pere mpe (MRD) dị ịrịba ama - mgbagha zuru oke mgbe ọgwụgwọ gasịrị. Site na 75% nkwụghachi ụgwọ zuru oke maka ọnya extramedullary yana otu afọ n'ozuzu nlanarị yana ọnụ ọgụgụ nlanarị na-enweghị ọrịa leukemia nke 58.5% na 51.4%, n'otu n'otu, ụzọ ọhụrụ a na-enye olileanya ọhụrụ maka mgbaghara ogologo oge na ọrịa cancer ndị a na-eme ihe ike.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4.CAR-T ọgwụgwọ maka B-Cell Acute Lymphoblastic leukemia: arụmọrụ na-enwetụbeghị ụdị ya.

Nnyocha e mere n'oge na-adịbeghị anya na-akọwapụta nrụpụta pụrụ iche nke chimeric antigen receptor-T cell (CAR-T) n'ịgwọ ọrịa leukemia nnukwu lymphoblastic B-cell (B-ALL). Emere ya na BIOOCUS na Ụlọ Ọgwụ Lu Daopei, nchọpụta ahụ gosipụtara na ọnụ ọgụgụ dị ịrịba ama nke ndị ọrịa nwetara mgbaghara zuru oke, na-edobe ọgwụgwọ CAR-T dịka nhọrọ ọgwụgwọ na-eduga maka ọrịa leukemia na-eme ihe ike. Nsonaazụ na-ekwe nkwa na-egosipụta ike mgbanwe nke ọgwụgwọ CAR-T na oncology, na-enye olileanya maka ndị ọrịa na ezinụlọ na-eche B-ALL ihu. Ka nyocha na-aga n'ihu, a na-ahazi ọgwụgwọ CAR-T ka ọ rụọ ọrụ dị mkpa n'ọdịnihu ọgwụgwọ ọrịa kansa.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

Usoro ọgwụgwọ CAR-T

Mkpokọta 1.T-cell:

Na mbụ, ndị dọkịta na-anakọta mkpụrụ ndụ T n'ọbara onye ọrịa na-eji usoro a na-akpọ leukapheresis. Usoro a na-ewekarị ihe dị ka awa 4, mgbe onye na-ekewa ọbara na-ekewapụ mkpụrụ ndụ ọbara ọcha achọrọ ma weghachi ihe ndị fọdụrụ n'ahụ onye ọrịa.

2.Mgbanwe mkpụrụ ndụ ihe nketa na Mgbasawanye:

A na-eziga mkpụrụ ndụ T ndị anakọtara na ụlọ nyocha maka mgbanwe mkpụrụ ndụ ihe nketa. N'ime usoro a, a na-emezi mkpụrụ ndụ T iji lekwasị anya na ibibi mkpụrụ ndụ kansa. Usoro a na-ewe ihe dịka izu 2-3. N'oge a, mkpụrụ ndụ T na-arụ ọrụ ma gbasaa n'ime ụlọ nyocha iji hụ na ọ dị irè megide ọrịa cancer.

3. Mkpịsị mkpụrụ ndụ:

Mgbe mkpụrụ ndụ T ndị e mezigharịrị emezigharị, a na-eweghachi ha n'ahụ onye ọrịa site na mmịnye eriri afọ. Nzọụkwụ a na-enye ohere ka mkpụrụ ndụ na-alụso ọrịa ọgụ gbanwetụrụ ịmata ma kpochapụ mkpụrụ ndụ kansa nke ọma.

Ndị ọrịa nwere ike ịnwe mmetụta ndị na-adịghị mma n'oge ọgwụgwọ, nke a na-ahụkarị bụ cytokine release syndrome (CRS), nke mmeghachi omume mgbochi na-akpata n'oge mbibi mkpụrụ ndụ cancer na-arụ ọrụ. Ọ bụ ezie na CRS nwere ike ịdị njọ, ọganihu na nlekọta ahụike ebelatala ihe egwu ya.

Usoro ọgwụgwọ dum, site na nchịkọta cell ruo na infusion, na-adịkarị izu 4-6, n'agbanyeghị na ogologo oge ahụ dabere na ọnọdụ onye ọrịa ahụ kpọmkwem.

Nkwado zuru oke maka ndị ọrịa mba ụwa na-eme njem na BIOOCUS maka ọgwụgwọ CAR-T

Na BIOOCUS, anyị raara onwe anyị nye inye nlekọta na nkwado pụrụ iche maka ndị ọrịa mba ụwa na-achọ ọgwụgwọ CAR-T. Ọrụ anyị zuru oke na-ekpuchi nzọụkwụ ọ bụla nke njem ahụ, site na nkwadebe tupu njem gaa na nlekọta nlekọta ọgwụgwọ.

1.Nkwadebe tupu njem

Tupu ha eme njem na BIOOCUS, ndị ọrịa ga-enyocha nyocha nke ọma n'ụlọ ọgwụ mpaghara ha. Nke a na-agụnye nyocha nke ọma nke akụkọ ihe mere eme ahụike, nyocha anụ ahụ, na nyocha ndị dị mkpa dị ka ọrụ ọbara, nchọpụta foto, na nyocha kpọmkwem maka ụdị ọrịa cancer a na-agwọ (dị ka leukemia, lymphoma, ma ọ bụ ọrịa cancer ọbara ndị ọzọ). Anyị na-ahụ na a na-ezigara ndị otu anyị akwụkwọ ndekọ ahụike niile, gụnyere ọgwụgwọ mbụ, nsonaazụ ule, na nkwenye nchoputa, na ndị otu anyị maka nyocha na nkwadebe.

2. Njem na ụlọ ọgwụ

Anyị na-enyere aka n'akụkụ niile nke njem, gụnyere ịhazi ebe obibi na ndoputa ndị ọrịa na BIOOCUS International Medical Center. Mgbe ọ bịarutere, a na-eduzi ndị ọrịa site na usoro nnabata, na-eme ka mgbanwe dị mma na gburugburu ebe ọgwụgwọ.

3. Usoro ọgwụgwọ

Mgbe nnabata, ndị ọrịa ga-enweta usoro nyocha nke mbido, gụnyere nyocha iji hụ na ntozu maka ọgwụgwọ CAR-T. Nke a ga-agụnye nyochaa ọnọdụ ọrịa kansa nke onye ọrịa na ahụike zuru oke, yana nchịkọta ọbara maka mmịpụta T-cell. A na-ezigakwa cell T-e kpokọtara na ụlọ nyocha nke GMP anyị kwadoro maka mgbanwe mkpụrụ ndụ ihe nketa. Usoro a nwere ike were ihe dịka izu 2-3.

4.Cell infusion na Post-treatment Care

Ozugbo mkpụrụ ndụ CAR-T gbanwechara, ndị ọrịa ga-alaghachi n'ụlọ ọgwụ anyị maka usoro infusion. Nke a bụ ọgwụgwọ otu oge ebe a na-enye cell T-engineered intravenously. Na-eso infusion, ndị ọrịa ga-anọ n'okpuru anya nke ọma ruo ọtụtụ ụbọchị iji nyochaa maka mmetụta dị n'akụkụ, dị ka cytokine release syndrome, nke nwere ike imeghachi omume na ọgwụgwọ. Ndị otu ahụike anyị na-enye nkwado na nleba anya na-aga n'ihu n'oge oge a dị oke egwu.

Mgbe ahapụchara ya, BIOOCUS na-ahazi nleta nleba anya mgbe niile, gụnyere nyocha ụlọ nyocha na nyocha onyonyo, iji nyochaa ịdị mma nke ọgwụgwọ yana soro mgbake onye ọrịa ahụ. A ga-enyocha ndị ọrịa nke ọma maka mmetụta ọ bụla nke ọgwụgwọ oge na-abịa, na ndị otu anyị ga-anọgide na-akpọtụrụ iji nye nduzi na nkwado na-aga n'ihu.

Na BIOOCUS, anyị na-ebute ahụike, nchekwa na nkasi obi nke ndị ọrịa mba ụwa anyị ụzọ. Ebumnuche anyị bụ ịnye nlekọta zuru oke ma hụ na a na-enye nkwado, ahụmahụ na-enweghị isi na njem nlekọta CAR-T.

Maka ozi ndị ọzọ gbasara ọrụ anyị yana otu anyị nwere ike isi nyere aka na ọgwụgwọ gị, biko kpọtụrụ anyị ozugbo.

nkọwa2

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.